Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study

NCT07200375 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07200375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07200375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Recruiting
Start date
September 29, 2025
Completion date
September 29, 2029
Enrollment
300 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma